Since 2008, across over 180 published trials, and 15,000 stimulation sessions, the Soterix Medical 1x1 tDCS is the recognized standard in tDCS research. The 1x1 tDCS anchors the 1x1 class of stimulators, with unique features such as RELAX, SmartSCAN, and TrueCurrent with exhaustively validated accessories. The upgraded 1x1 tDCS includes LTE and Adaptive Current to 5 mA.
Proven for safe and tolerable tDCS: Higher intensity stimulation is made possible using a combination of stimulator and our accessories.
The Soterix Medical 1x1 tDCS was developed by clinical researchers, scientists, and biomedical engineers to precisely provide all tDCS research and clinical protocols. Pioneering and pivotal tDCS trials have relied on the 1x1 platform, which stands out for simple set-up and programming, intuitive controls, and seamless integration with best-in-class tDCS accessories. Unique features allow you to focus on the subject and experiment, not the device. The Soterix Medical 1x1 tDCS is the standard for precise and reproducible tDCS.
Current intensity from 0.1 to 5 mA, and current duration from 5 to 40 minutes. Higher current performance is made possible by unique accessories, integrated LTE and Adaptive current ramp. The 1x1 tDCS is capable of delivering higher tolerated doses than any other system. At conventional tDCS doses, such as 1 mA and 2 mA, the 1x1 tDCS provides the most tolerated stimulation, which means studies using the 1x1 tDCS also have the best compliance and most reliable sham performance. The Soterix Medical 1x1 platform provides more reliable current delivery because it is based on the most advanced device and accessory technology. Whether you want to apply standard tDCS protocols, or establish new ones, our scientific team is ready to work with you to determine optimal dose parameters and accessories.
The Soterix Medical 1x1 platform is the most accurate tDCS technology available. Built into every 1x1 device are the most advanced monitoring and control systems updating performance and feedback over 1000 times per second. Stimulation output fidelity (signal-to-noise) is maintained during the entire stimulation session even if electrode conditions change. Precise control of output waveform is essential for stimulation efficacy and safety.
Clinical trials with Soterix Medical 1x1 tDCS remove uncertainty about device output and ensure results are meaningful and reproducible.*
*Soterix Medical Inc. can no longer provide tDCS accessories, HD-adaptors, neurotargeting software, or Solution Support for unverified devices by other manufacturers.
Advanced real-time control and optimization
In developing the 1x1, feed-back from leading clinical centers was clear: stimulation must be simple to program and its status must always be apparent to the investigator. With a simple press of a button to set stimulation duration and intensity, and back-lit status displays visible in dim or bright room light, the Soterix Medical Open-Panel™ design takes the guess work out of the stimulation.
Soterix Medical 1x1 tDCS system is the only validated device for high-intensity applications.
Each Soterix Medical 1x1 feature was developed by our team of biomedical engineers consulting closely with leading clinical centers. Designed to simply set-up, provide intelligent warning of a fault condition, and allow for adjustments for patient comfort, these features facilitate reliable and tolerated tDCS. The Soterix Medical SmartScan™ feature is central in all tDCS devices to allow reliable set-up and monitoring. The RELAX™, Tickle™, and TrueCurrent™ innovations were developed for the 1x1 tDCS.
Provides a continuous visual indication of electrode quality before and during stimulation.
From pre-stimulation set-up, to during stimulation monitoring, to post-stimulation confirmation, the Soterix Medical SmartScan™ feature provides an intuitive and clear indication of electrode contact quality. Use the SmartScan™ during set-up to adjust electrodes and head-gear for optimal fit. During stimulation, SmartScan™ provides a constant indication of electrode quality and can be monitored during adjustments (e.g. addition of saline to drying electrodes). After stimulation, SmartScan™ confirms a successful trial. Because “resistance” is not meaningful for tDCS, SmartScan™ was developed by Soterix Medical engineers to provide clinical investigators with a simple to read indication of contact quality.
Clearly indicates the actual current supplied at the moment.
What other devices promise, the 1x1 tDCS delivers. The back-lit display can be monitored during stimulation ramp up to confirm that the targeted current intensity is achieved.
May be used to supply a very weak current prior to tDCS to help condition the skin.
Tickle™ may be used to both condition skin prior to tDCS and for naïve subjects who are anxious about stimulation. A custom on-off waveform pattern generates mild and brief sensation under electrodes.
Allows the clinician to use slider buttons to transiently decrease or increase the current from the pre-set value, for example, based on subject feedback.
Based on feed-back from leading clinical centers, Soterix Medical exclusive feature, RELAX™, accommodates subjects who may be anxious when stimulation is initiated or during the course of stimulation. The RELAX™ level may be adjusted from full to reduced intensity based on subject perception without interrupting or aborting stimulation.
Simple and intelligent sham waveforms.
An automatic stimulation sham feature that is engaged with a simple switch. Auto-sham automatically calculated and produces a sham waveform based on the indicated “real” waveform. For example, for a corresponding real waveform of 1.5 mA and 10 minutes. auto-sham will provide a ramp up/down to 1.5 mA at the start of of stimulation, and again after 10 minutes, with the timer automatically adjusted such that the total run time us exactly matched to the real case. Based on the Soterix Medical Open-Panel™ design principle: with no complicated programming or hidden drop-down menus required.
The lowest noise tDCS device ever, for combination with EEG recording.
Available only by special request, the +EEG mode on the 1x1-tDCS is a unique device especially designed for combination with EEG recording. All standard 1x1-tDCS devices already provide industry standard precision and low-noise output control. The +EEG mode of the 1x1-tDCS is a unique product only for EEG application where “floor level” noise is required from the simulator for theoretically maximized EEG S/N. Contact Soterix Medical professional support for guidance.
Every 1x1 accessory is optimized for simple and consistent set-up, robust and safe performance, and ease of use. Since "one size does not fit all" in tES, the 1x1 accessory set provides the flexibility to optimize performance. From EASYpads™ to EASYstraps™ Soterix Medical 1x1 accessories are designed and validated specifically for the 1x1 platform. Our scientific team is ready to help you select the best accessory set to make your 1x1 the most optimized platform adjustable to any application.
Optimization of electrode montage for brain targeting and individual subject customization has never been as easy as with Soterix Medical's Neurotargeting software. With recognition that placing an electrode "over" a target does not support rational tDCS does design, the Soterix Medical Suite of software tools allow simple and automatic optimization. Soterix Neurotargeting software also provides high-resolution current flow visualization that can be used to support publications, presentation and proposals.
Caution! Investigational Device. Federal (or the United States) law limits the device to investigational use. Soterix Medical tDCS-LTE therapy is available in select regions including the EU.
Recognizing and putting an electrode “over” a brain region and the other electrode at a “return” location does not optimize current delivery to that brain region. Stimulation of the dorsolateral prefrontal cortex (DLPFC) was optimized using computer simulations and the modeling methods used have been experimentally validated to be precise and optimized across subject head anatomy. The resulting montage was the “Omni-Lateral-Electrode-System” (OLE-System), which is superior to any EEG 10-10 based system including F3-F4 and to the other rules (e.g. BEAM F3).
The Pursuit of DLPFC: Non-neuronavigated Methods to Target the Left Dorsolateral Pre-frontal Cortex With Symmetric Bicephalic Transcranial Direct Current Stimulation (tDCS). Brain Stimul. 2015 May-Jun;8(3):590-602. doi: 10.1016/j.brs.2015.01.401.
Soterix Medical is the pioneer and industry leader in tDCS technology from the first medical-grade tDCS electrodes to head-gear designed for reliable and simple electrode positioning. The OLE-System for electrode placement optimized for DLPFC stimulation is triangulated through simple anatomical landmarks and the OLE SNAPstrap achieves this electrode placement in seconds. tDCS protocols are only as reproducible as the electrode design and placement. SNAPstrap system combined with SNAPpad electrodes is extremely robust and it was validated even under self-application in a patient population with motor deficits (MS).
Remotely-delivered cognitive remediation in multiple sclerosis (MS): protocol and results from a pilot study. Mult Scler J Exp Transl Clin. 2015 Oct 5;1:2055217315609629. doi: 10.1177/2055217315609629.
The OLE montage for DLPFC activation along with Soterix Medical LTE stimulation technology was validated in a series of clinical trials including for Depression. Two double-blind controlled clinical trials for Depression established the statically significant superiority of tDCS using OLE and LTE technology over placebo as either a stand-alone or add-on to pharmacotherapy treatment. Read the press release here. From model-driven design to optimized head-gear, to rigorous clinical trials, this Soterix Medical case use demonstrates the value of advanced technology for target engagement and compliance control.
Efficacy and Safety of Transcranial Direct Current Stimulation as an Add-on Treatment for Bipolar Depression: A Randomized Clinical Trial. JAMA Psychiatry. 2018 Feb 1;75(2):158-166. doi: 10.1001/jamapsychiatry.2017.4040.